



## ASX Release

### **Prescient Therapeutics Featured on Bloomberg's The RedChip Money Report**

Melbourne, Australia - (March 2, 2016) – The new CEO of clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX), Steven Yatomi-Clarke, will appear on Bloomberg Network's *The RedChip Money Report* later this week. Mr Yatomi-Clarke's interview with host Dave Gentry will air on Sunday, March 6, at 3:30 p.m. HKT on Bloomberg Asia, and 5:30 p.m. AET on Bloomberg Australia.

The interview segment can be previewed online <http://www.redchip.com/media/1405/prescient-therapeutics-novel-treatments-for-a-range-of-cancers>.

"The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, and financial book reviews, as well as featured interviews with executives of public companies. Dave Gentry is a leading authority on small-cap stocks and the author of *Small Stocks, Big Money*, published by Wiley Finance. Gentry has made multiple guest appearances on both CNBC and Fox Business News.

#### ENDS

#### **About Prescient Therapeutics Limited (PTX)**

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and at Florida's H. Lee Moffitt Cancer Center (Moffitt). A Phase Ib/II trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX has recently received IND allowance for a Phase Ib/II trial evaluating PTX-200 as a new therapy for Acute Myeloid Leukemia.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

#### **Further Inquiries:**

**Steven Yatomi-Clarke**  
CEO & Managing Director  
+61 417 601 440

**Paul Hopper**  
Executive Director  
+61 406 671 515

**Rudi Michelson**  
Monsoon Communications  
+61 3 9620 3333